From: 11th European Headache Federation Congress jointly with 31st Congress of the Italian Society for the Study of Headaches
Erenumab, mg
70 (N=2128)a
140 (N=1198)a
Subjects who experienced an ISR-AE, n (%)
130 (6.1)
50 (4.2)
Total time at risk summed across subjects, years
1738
649
Exposure-adjusted subject incidence rate per 100 subject-years
7.5
7.7